Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 374

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 374
---
 professionals will review and approve AI -drivenguidance as appropriate, specifically relating to medical diagnosis, and users will have access to human support if needed. Oversight will be maintained through established protocols and professional networks to ensure quality, safety, and compliance with evolving regulatory standards. For more information, see “ Risk Factors — Risks Related to Our Business and Stra tegy — Our fu ture AI Agents business will significantly depend upon third -party infrastructures, including language models and other AI technologies, which are subject to developing regulatory frameworks.” Before the transition to the business -to-business-to-consumermodel, the specialists prepared a personalized habits plan based on user lifestyle data, health risk indicators from their results, and health goals, which range from achieving a healthy weight, to optimizing physical performance and immunology, and mitigating disease development to impact longevity. These insights and methodologies will help to develop AI Agents, which will deliver personalized recommendations and action plans at scale. These action plan will set achievable objectives that would foster changes in intestinal microbiome results, thus benefiting our user’s health. Further, users would receive supplementary materials, including recipe books and other personalized content to support habit changes. Continuous Evolution Kit Starting in the fourth quarter of 2024, customers were provided with the option to purchase independent gut microbiome tests by purchasing the “Continuous Evolution Kit,” that collects stool samples for gut microbiome analysis. These customers will also be able to purchase the “Complete Profile Kit” to obtain more holistic results and health recommendations, by integrating their DNA data with their results. The updated microbiome results allow customers to keep track of their progress and compare with earlier results. In the pilot phase, the telemedicine session focused on reviewing significant results from the report and the progress made, resolving any queries about results, analyzing changes in the intestinal microbiome to make necessary lifestyle adjustments, setting new goals based on these results, and revising unmet goals to align with the customer’s lifestyle for future success. After the updated habit plan is provided, customers can repurchase the “Continuous Evolution Kit” to perpetuate their lifestyle improvement, thus creating a continuous cycle of health improvement. Heritas Diagnostics: Clinical Diagnostics, Prognosis, and Monitoring Heritas Diagnostics offers a comprehensive suite of genetic tests that processes high -qualitygenetic and clinical data, instrumental in enhancing clinical healthcare decisions. The tests are designed to supply precise genetic insights to doctors, patients, and their families for diagnosis, prognosis and monitoring, allowing them to make informed treatment decisions over various conditions. Currently